Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease

H. Matsuda, K. Hayashi, T. Saruta

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Although the angiotensin receptor antagonist (ARB) shares the angiotensin-ll-blocking activity with the angiotensin-converting enzyme inhibitor (ACE-I), pharmacological mechanisms of action of these agents differ. We evaluated the temporal profiles of action of ACE-I and ARB on urinary protein excretion and nitrate/nitrate (NOx) excretion in hypertensive (140 and/or 90mmHg) patients with chronic renal disease (serum creatinine <265 (range, 44-265)μmol/l or creatinine clearance > 30 (range, 30-121)ml/min). Patients with mild (<1 g/day; range, 0.4-1.0) and moderate proteinuria (>1 g/day; range, 1.1-6.9) were randomly assigned to ACE-I- and ARB-treated groups, and were treated with ACE-I (trandolapril or perindopril) or ARB(losartan or candesartan) for 48 weeks. In all groups, treatment with ACE-I or ARB decreased blood pressure to the same level, but had no effect on creatinine clearance. In patients with mild proteinuria, neither ACE-I nor ARB altered urinary protein excretion. In patients with moderate proteinuria, ACE-I caused 44 ± 6% reduction in proteinuria (from 2.7 ± 0.5 to 1.5 ± 0.4 g/day, n = 14) at 12 weeks, and this beneficial effect persisted throughout the protocol (48 weeks, 1.2 ± 0.2 g/day). In contrast, ARB did not produce a significant decrease in proteinuria at 12 weeks (23 ± 8%, n = 13), but a 41 ± 6% reduction in proteinuria was observed at 48 weeks. Similarly, although early (12 weeks) increases in urinary NOx excretion were observed with ACE-I (from 257 ± 70 to 1111 ± 160 μmol/day) and ARB (from 280 ± 82 to 723 ± 86 μmol/day), the ARB-induced increase in NOx excretion was smaller than that by ACE-I (P<0.05). In conclusion, although both ACE-I and ARB reduce blood pressure similarly, the effect of these agents on proteinuria differs in chronic renal disease with moderate proteinuria. Relatively early onset of the proteinuria-reducing effect was observed with ACE-I, which paralleled the increase in urinary NOx excretion. Conversely, ARB decreased proteinuria and increased urinary NOx excretion gradually. These time course-dependent changes in proteinuria and urinary NOx may reflect the pharmacological property of ACE-I and ARB, with regard to the action on bradykinin.

Original languageEnglish
Pages (from-to)271-276
Number of pages6
JournalJournal of Human Hypertension
Volume17
Issue number4
DOIs
Publication statusPublished - 2003 Apr 1

Fingerprint

Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Proteinuria
Kidney
trandolapril
Nitrates
Creatinine
Molecular Mechanisms of Pharmacological Action
Perindopril
Blood Pressure
Losartan
Angiotensins
Bradykinin
Proteins
Pharmacology

Keywords

  • Angiotensin receptor antagonists
  • Angiotensin-converting enzyme
  • Nitric oxide
  • Proteinuria
  • Renal protection

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease. / Matsuda, H.; Hayashi, K.; Saruta, T.

In: Journal of Human Hypertension, Vol. 17, No. 4, 01.04.2003, p. 271-276.

Research output: Contribution to journalArticle

@article{9f761e8b285b4e5dabaa7119ee3ecb57,
title = "Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease",
abstract = "Although the angiotensin receptor antagonist (ARB) shares the angiotensin-ll-blocking activity with the angiotensin-converting enzyme inhibitor (ACE-I), pharmacological mechanisms of action of these agents differ. We evaluated the temporal profiles of action of ACE-I and ARB on urinary protein excretion and nitrate/nitrate (NOx) excretion in hypertensive (140 and/or 90mmHg) patients with chronic renal disease (serum creatinine <265 (range, 44-265)μmol/l or creatinine clearance > 30 (range, 30-121)ml/min). Patients with mild (<1 g/day; range, 0.4-1.0) and moderate proteinuria (>1 g/day; range, 1.1-6.9) were randomly assigned to ACE-I- and ARB-treated groups, and were treated with ACE-I (trandolapril or perindopril) or ARB(losartan or candesartan) for 48 weeks. In all groups, treatment with ACE-I or ARB decreased blood pressure to the same level, but had no effect on creatinine clearance. In patients with mild proteinuria, neither ACE-I nor ARB altered urinary protein excretion. In patients with moderate proteinuria, ACE-I caused 44 ± 6{\%} reduction in proteinuria (from 2.7 ± 0.5 to 1.5 ± 0.4 g/day, n = 14) at 12 weeks, and this beneficial effect persisted throughout the protocol (48 weeks, 1.2 ± 0.2 g/day). In contrast, ARB did not produce a significant decrease in proteinuria at 12 weeks (23 ± 8{\%}, n = 13), but a 41 ± 6{\%} reduction in proteinuria was observed at 48 weeks. Similarly, although early (12 weeks) increases in urinary NOx excretion were observed with ACE-I (from 257 ± 70 to 1111 ± 160 μmol/day) and ARB (from 280 ± 82 to 723 ± 86 μmol/day), the ARB-induced increase in NOx excretion was smaller than that by ACE-I (P<0.05). In conclusion, although both ACE-I and ARB reduce blood pressure similarly, the effect of these agents on proteinuria differs in chronic renal disease with moderate proteinuria. Relatively early onset of the proteinuria-reducing effect was observed with ACE-I, which paralleled the increase in urinary NOx excretion. Conversely, ARB decreased proteinuria and increased urinary NOx excretion gradually. These time course-dependent changes in proteinuria and urinary NOx may reflect the pharmacological property of ACE-I and ARB, with regard to the action on bradykinin.",
keywords = "Angiotensin receptor antagonists, Angiotensin-converting enzyme, Nitric oxide, Proteinuria, Renal protection",
author = "H. Matsuda and K. Hayashi and T. Saruta",
year = "2003",
month = "4",
day = "1",
doi = "10.1038/sj.jhh.1001543",
language = "English",
volume = "17",
pages = "271--276",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease

AU - Matsuda, H.

AU - Hayashi, K.

AU - Saruta, T.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Although the angiotensin receptor antagonist (ARB) shares the angiotensin-ll-blocking activity with the angiotensin-converting enzyme inhibitor (ACE-I), pharmacological mechanisms of action of these agents differ. We evaluated the temporal profiles of action of ACE-I and ARB on urinary protein excretion and nitrate/nitrate (NOx) excretion in hypertensive (140 and/or 90mmHg) patients with chronic renal disease (serum creatinine <265 (range, 44-265)μmol/l or creatinine clearance > 30 (range, 30-121)ml/min). Patients with mild (<1 g/day; range, 0.4-1.0) and moderate proteinuria (>1 g/day; range, 1.1-6.9) were randomly assigned to ACE-I- and ARB-treated groups, and were treated with ACE-I (trandolapril or perindopril) or ARB(losartan or candesartan) for 48 weeks. In all groups, treatment with ACE-I or ARB decreased blood pressure to the same level, but had no effect on creatinine clearance. In patients with mild proteinuria, neither ACE-I nor ARB altered urinary protein excretion. In patients with moderate proteinuria, ACE-I caused 44 ± 6% reduction in proteinuria (from 2.7 ± 0.5 to 1.5 ± 0.4 g/day, n = 14) at 12 weeks, and this beneficial effect persisted throughout the protocol (48 weeks, 1.2 ± 0.2 g/day). In contrast, ARB did not produce a significant decrease in proteinuria at 12 weeks (23 ± 8%, n = 13), but a 41 ± 6% reduction in proteinuria was observed at 48 weeks. Similarly, although early (12 weeks) increases in urinary NOx excretion were observed with ACE-I (from 257 ± 70 to 1111 ± 160 μmol/day) and ARB (from 280 ± 82 to 723 ± 86 μmol/day), the ARB-induced increase in NOx excretion was smaller than that by ACE-I (P<0.05). In conclusion, although both ACE-I and ARB reduce blood pressure similarly, the effect of these agents on proteinuria differs in chronic renal disease with moderate proteinuria. Relatively early onset of the proteinuria-reducing effect was observed with ACE-I, which paralleled the increase in urinary NOx excretion. Conversely, ARB decreased proteinuria and increased urinary NOx excretion gradually. These time course-dependent changes in proteinuria and urinary NOx may reflect the pharmacological property of ACE-I and ARB, with regard to the action on bradykinin.

AB - Although the angiotensin receptor antagonist (ARB) shares the angiotensin-ll-blocking activity with the angiotensin-converting enzyme inhibitor (ACE-I), pharmacological mechanisms of action of these agents differ. We evaluated the temporal profiles of action of ACE-I and ARB on urinary protein excretion and nitrate/nitrate (NOx) excretion in hypertensive (140 and/or 90mmHg) patients with chronic renal disease (serum creatinine <265 (range, 44-265)μmol/l or creatinine clearance > 30 (range, 30-121)ml/min). Patients with mild (<1 g/day; range, 0.4-1.0) and moderate proteinuria (>1 g/day; range, 1.1-6.9) were randomly assigned to ACE-I- and ARB-treated groups, and were treated with ACE-I (trandolapril or perindopril) or ARB(losartan or candesartan) for 48 weeks. In all groups, treatment with ACE-I or ARB decreased blood pressure to the same level, but had no effect on creatinine clearance. In patients with mild proteinuria, neither ACE-I nor ARB altered urinary protein excretion. In patients with moderate proteinuria, ACE-I caused 44 ± 6% reduction in proteinuria (from 2.7 ± 0.5 to 1.5 ± 0.4 g/day, n = 14) at 12 weeks, and this beneficial effect persisted throughout the protocol (48 weeks, 1.2 ± 0.2 g/day). In contrast, ARB did not produce a significant decrease in proteinuria at 12 weeks (23 ± 8%, n = 13), but a 41 ± 6% reduction in proteinuria was observed at 48 weeks. Similarly, although early (12 weeks) increases in urinary NOx excretion were observed with ACE-I (from 257 ± 70 to 1111 ± 160 μmol/day) and ARB (from 280 ± 82 to 723 ± 86 μmol/day), the ARB-induced increase in NOx excretion was smaller than that by ACE-I (P<0.05). In conclusion, although both ACE-I and ARB reduce blood pressure similarly, the effect of these agents on proteinuria differs in chronic renal disease with moderate proteinuria. Relatively early onset of the proteinuria-reducing effect was observed with ACE-I, which paralleled the increase in urinary NOx excretion. Conversely, ARB decreased proteinuria and increased urinary NOx excretion gradually. These time course-dependent changes in proteinuria and urinary NOx may reflect the pharmacological property of ACE-I and ARB, with regard to the action on bradykinin.

KW - Angiotensin receptor antagonists

KW - Angiotensin-converting enzyme

KW - Nitric oxide

KW - Proteinuria

KW - Renal protection

UR - http://www.scopus.com/inward/record.url?scp=0038736940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038736940&partnerID=8YFLogxK

U2 - 10.1038/sj.jhh.1001543

DO - 10.1038/sj.jhh.1001543

M3 - Article

C2 - 12692572

AN - SCOPUS:0038736940

VL - 17

SP - 271

EP - 276

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 4

ER -